Challenging the Myths in Heart Failure With Reduced Ejection Fraction

Myth #1: My HFrEF Patient Is Stable and Is Out of Danger

Other Questions to Consider……

Myth #2: We Should Start Low and Go Slow With Drug Uptitrations

ATLAS Trial: Dose Response in HF

Considerations for Uptitration in HFrEF

Uptitration of HF Therapies How Do We Overcome the Delays?

Reasons Drug Uptititration Does Not Occur

What are the Goals for Uptitration?

Myth #3: My HFrEF Patient Does Not Need an MRA

ESC Guidelines for Chronic HF

ESC HF Long-Term Registry Use of Pharmacological Therapies

MRAs in HF

MRA Use in the Elderly

Ontario Study: Hyperkalemia With MRAs

Myth #4: My HFrEF Patient Does Not Need an ARNI

PARADIGM-HF: Cardiovascular Death or Heart Failure Hospitalization (Primary Endpoint)

ACE Inhibitor vs ARNI

PARADIGM HF: Adverse Events With Sacubitril/Valsartan

PARADIGM-HF: Angioedema

Sacubitril/Valsartan in HFrEF: Starting Dose and Dose Titration

Myth #5: My HFrEF Patient Has Multiple Comorbidities and HF in This Context Is Very Difficult to Manage

COPD and Heart Failure

Atrial Fibrillation and HF

Diabetes and Heart Failure

Abbreviations

Abbreviations (cont)